BriaCell Therapeutics Corp.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Emerging growth company
State of Incorporation
British Columbia, Canada
Business Address
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER, A1, V7T 2X1
Mailing Address
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER, A1, V7T 2X1
Phone
(604) 921-1810
Fiscal Year End
0731
EIN
000000000
Financial Overview
FY2025
-$4.79M
Net Income
$21.65M
Total Assets
$10.49M
Cash & Equivalents
$-43.68
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 31, 2026 | View on SEC |
| 10-Q Quarterly financial report | March 10, 2026 | View on SEC |
| 8-K Current report of material events | March 9, 2026 | View on SEC |
| 8-K Current report of material events | February 20, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | February 12, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | January 23, 2026 | View on SEC |
| 8-K Current report of material events | January 15, 2026 | View on SEC |
| 424B4 Prospectus for IPO or offering | January 14, 2026 | View on SEC |
| 8-K Current report of material events | December 29, 2025 | View on SEC |
| S-1 IPO registration statement | December 23, 2025 | View on SEC |
Annual Reports
10-K
October 16, 2025
- Advanced Bria-IMT into Phase II trials with promising early results in some patients
- Earned FDA Fast Track designation for Bria-IMT
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.